Artículos de revistas
Brazilian Guidelines For The Treatment Of Narcolepsy [diretrizes Brasileiras Para O Tratamento Da Narcolepsia]
Registro en:
Revista Brasileira De Psiquiatria. , v. 32, n. 3, p. 305 - 314, 2010.
15164446
10.1590/S1516-44462010000300016
2-s2.0-77958506725
Autor
Aloe F.
Alves R.C.
Araujo J.F.
Azevedo A.
Bacelar A.
Bezerra M.
Bittencourt L.R.A.
Bustamante G.
De Oliveira Cardoso T.A.M.
Eckeli A.L.
Fernandes R.M.F.
Goulart L.
Pradella-Hallinan M.
Hasan R.
Sander H.H.
Pinto Jr. L.R.
Lopes M.C.
Minhoto G.R.
Moraes W.
Moreira G.A.
Pachito D.
Pedrazolli M.
Poyares D.
Prado L.
Rizzo G.
Rodrigues R.N.
Roitman I.
Silva A.B.
Tavares S.M.A.
Institución
Resumen
This manuscript contains the conclusion of the consensus meeting of the Brazilian Sleep Association with Brazilian sleep specialists on the treatment of narcolepsy based on the review of medical literature from 1980 to 2010. The manuscript objectives were to reinforce the use of agents evaluated in randomized placebo-controlled trials and to issue consensus opinions on the use of other available medications as well as to inform about safety and adverse effects of these medications. Management of narcolepsy relies on several classes of drugs, namely, stimulants for excessive sleepiness, antidepressants for cataplexy and hypnotics for disturbed nocturnal sleep. Behavioral measures are likewise valuable and universally recommended. All therapeutic trials were analyzed according to their class of evidence. Recommendations concerning the treatment of each single symptom of narcolepsy as well as general recommendations were made. Modafinil is the first-line pharmacological treatment of excessive sleepiness. Second-line choices for the treatment of excessive sleepiness are slow-release metylphenidate followed by mazindol. The first-line treatments of cataplexy are the antidepressants, reboxetine, clomipramine, venlafaxine, desvenlafaxine or high doses of selective serotonin reuptake inibitors antidepressants. As for disturbed nocturnal sleep the best option is still hypnotics. Antidepressants and hypnotics are used to treat hypnagogic hallucinations and sleep paralysis. 32 3 305 314 Morgenthaler, T.I., Kapur, V.K., Brown, T., Swick, T.J., Alessi, C., Aurora, R.N., Boehlecke, B., Zak, R., Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin (2007) Sleep, 30 (12), pp. 1705-1711. , Standards of Practice Committee of the American Academy of Sleep Medicine Sackett, D.L., Rules of evidence and clinical recommendations for the management of patients (1993) Can J Cardiol, 9 (6), pp. 487-489 Eddy, D., (1992) A Manual for Assessing Health Practices and Designing Practice Policies: The Explicit Approach, , Philadelphia: American College of Physicians Levels of Evidence, , http://www.cebm.net/index.aspx0=1025, Web Site. [cited 2009 dez 16]. Available from Delbecq, A., Vande Ven, A., A group process model for prob lem identification and programme planning (1971) J Appl Behav Sci, 7, pp. 467-492 Britton, T., Hansen, A., Hicks, J., Howard, R., Meredith, A., (2002) Guidelines on the Diagnosis and Management of Narcolepsy in Adults and Children. Evidence-Based Guidelines for the UK with Graded Recommendations, , Ashtead, UK: Taylor Patten Communications Ltd Guilleminault, C., Fromherz, S., Narcolepsy: Diagnosis and management (2005) Principles and Practice of Sleep Medicine, , Kryger MH, Roth T, Dement WC, editors. 4th ed. Philadelphia: Saunders, Elsevier Billiard, M., Bassetti, C., Dauvilliers, Y., Dolenc-Groselj, L., Lammers, G.J., Mayer, G., Pollmacher, T., Sonka, K., EFNS guidelines on management of narcolepsy (2006) Eur J Neurol, 13 (10), pp. 1035-1048 Wise, M.S., Arand, D.L., Auger, R.R., Brooks, S.N., Watson, N.F., Treatment of narcolepsy and other hypersomnias of central origin (2007) Sleep, 30 (12), pp. 1712-1727 Roehrs, T., Zorick, F., Wittig, R., Paxton, C., Sicklesteel, J., Roth, T., Alerting effects of naps in patients with narcolepsy (1986) Sleep, 9, pp. 194-199 Mullington, J., Broughton, R., Scheduled naps in the management of daytime sleepiness in narcolepsy- Cataplexy (1993) Sleep, 16 (5), pp. 444-456 Rogers, A.E., Aldrich, M.S., Lin, X., A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy (2001) Sleep, 24 (4), pp. 385-391 Chen, W., Mignot, E., Narcolepsy and hypersomnia of central origin: Diagnosis, differential pearls, and management (2007) Review of Sleep Medicine, pp. 75-94. , Barkoukis T, Avidan A, editors. 2nd ed. Philadelphia: Butterworth Heinman, Elsevier Zaharna, M., Dimitriu, A., Guilleminault, C., Expert opinion on pharmacotherapy of narcolepsy (2010) Expert Opin Pharmacother, , In press Zolkowska, D., Jain, R., Rothman, R.B., Partilla, J.S., Roth, B.L., Setola, V., Prisinzano, T.E., Baumann, M.H., Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil (2009) J Pharmacol Exp Ther, 329 (2), pp. 738-746 Boutrel, B., Koob, G.F., What keeps us awake: The neuropharmacology of stimulants and wakefulness-promoting medications (2004) Sleep, 27 (6), pp. 1181-1194 Volkow, N.D., Fowler, J.S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Hooker, J.M., Apelskog-Torres, K., Effects of modafinil on dopamine and dopamine transporters in the male human brain (2009) JAMA, 301 (11), pp. 1148-1154 Qu, W.M., Huang, Z.L., Xu, X.H., Matsumoto, N., Urade, Y., Dopamin ergic D1 and D2 receptors are essential for the arousal effect of modafinil (2008) J Neurosci, 28 (34), pp. 8462-8469 Beierlein, M., Gibson, J.R., Connors, B.W., A network of electrically coupled interneurons drives synchronized inhibition in neocortex (2000) Nat Neurosci, 3 (9), pp. 904-910 Hestrin, S., Galarreta, M., Electrical synapses define networks of neocortical GABAergic neurons (2005) Trends in Neurosciences, 28 (6 SPEC. ISS), pp. 304-309. , DOI 10.1016/j.tins.2005.04.001, PII S0166223605000998 Garcia-Rill, E., Heister, D.S., Ye, M., Charlesworth, A., Hayar, A., Electrical coupling: Novel mechanism for sleep-wake control (2007) Sleep, 30 (11), pp. 1405-1414 Urbano, F.J., Leznik, E., Llinas, R.R., Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling (2007) Proceedings of the National Academy of Sciences of the United States of America, 104 (30), pp. 12554-12559. , DOI 10.1073/pnas.0705087104 Beck, P., Odle, A., Wallace-Hunt, T., Skinner, R.D., Garcia-Rill, E., Modafinil increases arousal determined by P13 potential am plitude: An effect blocked by gap junction antagonists (2008) Sleep, 31 (12), pp. 1647-1654 Ferraro, L., Tanganelli, S., O'Connor, W.T., Antonelli, T., Rambert, F., Fuxe, K., The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: Possible involvement of the serotonergic 5-HT3 receptor (1996) Neuroscience Letters, 220 (1), pp. 5-8. , DOI 10.1016/S0304-3940(96)13212-2, PII S0304394096132122 Ferraro, L., Antonelli, T., O'Connor, W.T., Tanganelli, S., Rambert, F., Fuxe, K., The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus (1997) NeuroReport, 8 (13), pp. 2883-2887 De La Mora, M.P., Aguilar-Garcia, A., Ramon-Frias, T., Ramirez-Ramirez, R., Mendez-Franco, J., Rambert, F., Fuxe, K., Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus (1999) Neuroscience Letters, 259 (3), pp. 181-185. , DOI 10.1016/S0304-3940(98)00905-7, PII S0304394098009057 Willie, J.T., Renthal, W., Chemelli, R.M., Miller, M.S., Scammell, T.E., Yanagisawa, M., Sinton, C.M., Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates (2005) Neuroscience, 130 (4), pp. 983-995. , DOI 10.1016/j.neuroscience.2004.10.005, PII S0306452204009339 Scammell, T.E., Estabrooke, I.V., McCarthy, M.T., Chemelli, R.M., Yanagisawa, M., Miller, M.S., Saper, C.B., Hypothalamic arousal regions are activated during modafinil-induced wakefulness (2000) J Neurosci, 20 (22), pp. 8620-8628 Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy (1998) Ann Neurol, 43 (1), pp. 88-97. , US Modafinil in Narcolepsy Multicenter Study Group Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy (2000) Neurology, 54 (5), pp. 1166-1175. , US Modafinil in Narcolepsy Multicenter Study Group Broughton, R.J., Fleming, J.A.E., George, C.F.P., Hill, J.D., Kryger, M.H., Moldofsky, H., Montplaisir, J.Y., Murphy, W.F., Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy (1997) Neurology, 49 (2), pp. 444-451 Mitler, M.M., Hirsh, J., Hirshkowitz, M., Guilleminault, C., Long-term efficacy and safety of modafinil (PROVIGIL) for the treatment of excessive daytime sleepiness associated with narcolepsy (2000) Sleep Med, 1 (3), pp. 231-243. , for the US Modafinil in Narcolepsy Multicenter Study Group Moldofsky, H., Broughton, R.J., Hill, J.D., A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy (2000) Sleep Med, 1 (2), pp. 109-116 Schwartz, J., Feldman, N.T., Bogan, R.K., Dose response and dose regimen effects of modafinil in sustaining daytime wakefulness in narcoleptic patients with residual excessive sleepiness (2005) J Neuropsychiatry Clin Neurosci, 17 (3), pp. 405-412 Dauvilliers, Y., Neidhart, E., Billiard, M., Tafti, M., Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil (2002) Pharmacogenomics Journal, 2 (1), pp. 65-68. , DOI 10.1038/sj.tpj.6500088 Robertson Jr., P., Hellriegel, E.T., Clinical pharmacokinetic profile of modafinil (2003) Clin Pharmacokinet, 42 (2), pp. 123-137 Wong, Y.N., Simcoe, D., Hartman, L.N., Laughton, W.B., King, S.P., McCormick, G.C., Grebow, P.E., A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers (1999) Journal of Clinical Pharmacology, 39 (1), pp. 30-40. , DOI 10.1177/00912709922007534 Schawartz, J.R., Modafinil in the treatment of excessive sleepiness (2009) Drug des Devel Ther, 2, pp. 71-85 Kumar, R., Approved and investigational uses of modafinil: An evidence-based review (2008) Drugs, 68 (13), pp. 1803-1839 Walsleben, J.A., Ristanovic, R., Hirshkowitz, M., Provigil (modafinil) in the treatment of excessive daytime sleepiness in narcolepsy: Effect of previous treatment with stimulants on clinical response and safety (2000) Sleep, 23, pp. A303-4 Schwartz, J.R.L., Feldman, N.T., Fry, J.M., Harsh, J., Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants (2003) Sleep Medicine, 4 (1), pp. 43-49. , DOI 10.1016/s1389-9457(02)00240-x Thorpy, M.J., Schwartz, J.R.L., Kovacevic-Ristanovic, R., Hayduk, R., Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: An open-label safety study assessing three strategies (2003) Psychopharmacology, 167 (4), pp. 380-385 Roth, T., Schwartz, J.R.L., Hirshkowitz, M., Erman, M.K., Dayno, J.M., Arora, S., Evaluation of the safety of modafinil for treatment of excessive sleepiness (2007) Journal of Clinical Sleep Medicine, 3 (6), pp. 595-602 Jasinski, D.R., Kovacevi-Ristanovi, R., Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy (2000) Clin Neuropharmacol, 23 (3), pp. 149-156 Myrick, H., Malcolm, R., Taylor, B., LaRowe, S., Modafinil: Preclinical, clinical, and post-marketing surveillance - A review of abuse liability issues (2004) Ann Clin Psychiatry, 16 (2), pp. 101-106 Jasisnki, D.R., An evaluation of the abuse potential of modafinil using methylphenidate as a reference (2000) J Psychopharmacol, 14 (1), pp. 53-60 Andersen, M.L., Kessler, E., Murnane, K.S., McClung, J.C., Tufik, S., Howell, L.L., Dopamine transporter-related effects of modafinil in rhesus monkeys (2010) Pshychopharmacology, 210 (3), pp. 439-448. , Berl Provigil Consumer Information, , www.fda.gov/cder/consumerinfo/druginfo/provigil, [cited 2009 mar 2]. Available from Bogan, R.K., Armodafinil in the treatment of excessive sleepiness (2010) Expert Opin Pharmacother, 11 (6), pp. 993-1002 Nishino, S., Okuro, M., Emerging treatments for narcolepsy and its related disorders (2010) Expert Opin Emerg Drugs, 15 (1), pp. 139-158 Auger, R.R., Goodman, S.H., Silber, M.H., Krahn, L.E., Pankratz, V.S., Slocumb, N.L., Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study (2005) Sleep, 28 (6), pp. 667-672 Dauvilliers, Y., Arnulf, I., Mignot, E., Narcolepsy with cataplexy (2007) Lancet, 369 (9560), pp. 499-511 Mitler, M.M., Hajdukovik, R., Relative efficacy of drugs used for the treatment of narcolepsy (1991) Sleep, 14 (3), pp. 218-220 Wallin, M.T., Mahowald, M.W., Blood pressure effects of long-term stimulant use in disorders of hypersomnolence (1998) J Sleep Res, 7 (3), pp. 209-215 Thorpy, M., Current concepts in the etiology, diagnosis and treatment of narcolepsy (2001) Sleep Med, 2 (1), pp. 5-17 Mitler, M.M., Aldrich, M.S., Koob, G.F., Zarcone, V.P., Narcolepsy and its treatment with stimulants. ASDA standards of practice (1994) Sleep, 17 (4), pp. 352-371 Shindler, J., Schachter, M., Brincat, S., Parkes, J.D., Amphetamine, mazindol, and fencamfamin in narcolepsy (1985) Br Med J (Clin Res Ed), 290 (6476), pp. 1167-1170 Lijima, S., Sugita, Y., Teshima, Y., Hishikawa, Y., Therapeutic effects of mazindol on narcolepsy (1986) Sleep, 9 (1 PART 2), pp. 265-268 Alvarez, B., Dahlitz, M., Grimshaw, J., Parkes, J.D., Mazindol in long-term treatment of narcolepsy (1991) Lancet, 337 (8752), pp. 1293-1294 Mayer, G., Meier-Ewert, K., Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study (1995) Clin Neuropharmacol, 18 (4), pp. 306-319 Hublin, C., Partinen, M., Heinonen, E., Puuka, P., Salmi, T., Selegiline in the treatment of narcolepsy (1994) Neurology, 44 (11), pp. 2095-2101 Pratt, D.S., Dubois, R.S., Hepatotoxicity due to pemoline (Cylert): A report of two cases (1990) J Pediatr Gastroent Nutri, 10 (2), pp. 239-241 Nehra, A., Mullick, F., Ishak, K.G., Zimmerman, H.J., Pemoline-associated hepatic injury (1990) Gastroenterol, 99 (5), pp. 1517-1519 Beaumont, M., Batejat, D., Pierard, C., Coste, O., Doireau, P., Van Beers, P., Chauffard, F., Lagarde, D., Slow release caffeine and prolonged (64-h) continuous wakefulness: Effects on vigilance and cognitive performance (2001) Journal of Sleep Research, 10 (4), pp. 265-276. , DOI 10.1046/j.1365-2869.2001.00266.x Houghton, W.C., Scammell, T.E., Thorpy, M., Pharmacotherapy for cataplexy (2004) Sleep Med Rev, 8 (5), pp. 355-366 Vignatelli, L., D'Alessandro, R., Candelise, L., Antidepressant drugs for narcolepsy (2005) Cochrane Database Syst Rev, 20, p. 3. , CD0003724 Frey, J., Darbonne, C., Fluoxetine suppresses human cataplexy: A pilot study (1994) Neurology, 44 (4), pp. 707-709 Poceta, J.S., Hajdukovic, R., Mitler, M.M., Improvement in cataplexy with yohimbine and paroxetine: Case report (1994) Sleep Res, 23, p. 304 Thirumalai, S.S., Shubin, R.A., The use of citalopram in resistant cataplexy (2000) Sleep Med, 1 (4), pp. 313-316 Smith, M., Parkes, J.D., Dahlitz, M., Venlafaxine in the treatment of the narcoleptic syndrome (1996) J Sleep Res, 5, p. 217 Larrosa, O., De La Llave, Y., Bario, S., Granizo, J.J., Garcia-Bor Reguero, D., Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: A pilot study (2001) Sleep, 24 (3), pp. 282-285 Mayer, G., Meier-Ewert, K., Selegiline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study (1995) Clin Neuropharmacol, 18 (4), pp. 306-319 A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy (2002) Sleep, 25 (1), pp. 42-49. , US XYREM Multicenter Study Group Further evidence support ing the use of sodium oxybate for the treatment of cataplexy: A double-blind, placebo-controlled study in 228 patients (2005) Sleep Med, 6 (5), pp. 415-421. , U.S. XYREM Multicenter Study Group A double-blind placebo controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy (2005) J Clin Sleep Med, 1 (4), pp. 391-397. , XYREM International Study Group Black, J., Houghton, W.C., Sodium oxybate improves excessive daytime sleepiness in narcolepsy (2006) Sleep, 29 (7), pp. 939-946 Lammers, G.J., Bassetti, C., Billiard, M., Black, J., Broughton, R., Dauvilliers, Y., Ferini Strambi, L., Thorpy, M., Sodium oxybate is an effective and safe treatment for narcolepsy (2010) Sleep Med, 11 (1), pp. 105-106 Grozinger, M., Hartter, S., Hiemke, C., Griese, E.-U., Roschke, J., Interaction of modafinil and clomipramine as comedication in a narcoleptic patient (1998) Clinical Neuropharmacology, 21 (2), pp. 127-129 Wu, D., Victoria Otton, S., Inaba, T., Kalow, W., Sellers, E.M., Interactions of amphetamine analogs with human liver CYP2D6 (1997) Biochemical Pharmacology, 53 (11), pp. 1605-1612. , DOI 10.1016/S0006-2952(97)00014-2, PII S0006295297000142 Thorpy, M.J., Snyder, M., Aloe, F.S., Ledereich, P.S., Starz, K.E., Short-term triazolam use improves nocturnal sleep of narcoleptics (1992) Sleep, 15 (3), pp. 212-216 Bonakis, A., Howard, R.S., Ebrahim, I.O., Merritt, S., Williams, A., REM sleep behaviour disorder (RBD) and its associations in young patients (2009) Sleep Med, 10 (6), pp. 641-645 Suzanne Hoover-Stevens, S., Ruzica Kovacevic-Ristanovic, R., Management of narcolepsy in pregnancy (2000) CIin Neuropharmacol, 23 (4), pp. 175-181 Rogers, A.E., Aldrich, M.S., Berrios, A.M., Rosenberg, R.S., Compliance with stimulant medications in patients with narcolepsy (1997) Sleep, 20 (1), pp. 28-33